Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: C579- Malignant neoplasm of female genital organ, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
None
Eligibility
Inclusion criteria
Inclusion criteria: The following patients will be included: -The patients who have recovered from a COVID 19 infection and undergoing elective or emergency gynaecological cancer surgery excluding minor OT procedures done at TMH and ACTREC, Mumbai will be included. -The previous diagnosis of COVID 19 would be based on positive COVID-19 lab test. -Definition of COVID 19 positive: test positive [either the test undergone at Tata Memorial Hospital (TMH) or any centre outside TMH with reports] -Definition of COVID 19 negative : â??Test negativeâ?? at TMH/ACTREC. -Duration from COVID test: When the patient is COVID 19 negative and fit for surgery as per hospital protocol (generally patients undergo surgery 2 to 4 wks when COVID 19 test is negative). -The test is as per recommendations by National task force (ICMR) on COVID 19 during that period. As per the current ICMR advisory on strategy for COVID â?? 19 testing in India (Version VI, dated 04/09/2020), the current recommended tests are RT-PCR or TrueNat or CBNAAT, Rapid Antigen Test (RAT). -Definition of recovery: COVID 19 test negative and considered fit to undergo surgery. The study group would consist of recovered COVID 19 positive patients fit for surgery (Test negative at present, and fit for surgery).They had a past history of COVID 19 positivity ( Test positive at TMH / non-TMH) but currently, they are tested negative at TMH and fit for surgery. The control group would consist of COVID 19 Negative patients( Test negative at TMH/ACTREC) fit for surgery and without any past history of COVID 19 positivity. Consent will be obtained from both the study group and Control group patients included in the study.
Exclusion criteria
Exclusion criteria: The COVID 19 Positive patients undergoing /undergone surgery(those who were Test positive at the time of surgery) will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 30 and 90-day mortality/morbidity(DindoClavein grade I-V)Timepoint: 30 and 90-days after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Oncological outcomes at 12 months (DFS)Timepoint: 12 months after surgery | — |
Countries
India
Contacts
Public ContactDr Biswajit Dash
Tata Memorial Centre
Outcome results
None listed